Advertisement

Videos

Use of Amivantamab in patients with EGFR Exon 20–Positive Non–Small Cell Lung Cancer

May 6th 2022

An expert in the lung cancer and a representative from lung cancer advocacy group talk about the use of amivantamab, a novel therapy approved for treating EGFR exon 20 insertion–positive disease.

Access to Novel Therapy for EGFR Exon 20–Positive NSCLC

May 6th 2022

A brief discussion on the importance of accessing novel therapy and clinical trials in the setting of EGFR exon 20 insertion–positive NSCLC.

Patrick Dempsey Notes Mental Health in Cancer Care Has ‘Changed Tremendously’ Over Past 2 Decades

May 5th 2022

Mental wellbeing is more of a focus than ever before in cancer care, and while treatments continue to get better, there is still a long road ahead, according to Patrick Dempsey.

Unmet Needs and Future Perspectives in the Treatment of RCC

May 5th 2022

Bryan Lewis, president of KidneyCAN, and Chung-Han Lee, MD, describe unmet needs and future perspectives in the treatment of renal cell carcinoma.

The Importance of Patients Advocating for Themselves During Their RCC Journey

May 5th 2022

Meryl Uranga describes her path with metastatic clear cell renal cell carcinoma after first treatment, and how it has affected her outlook on her life and future.

Quality-of-Life with Systemic Therapies in Metastatic Clear Cell RCC

May 5th 2022

A look at how to consider quality-of-life clinical trial and patient-reported data when treating clear cell renal cell carcinoma with combination therapies.

Treating Radioiodine-Refractory DTC After Progression on Lenvatinib

May 5th 2022

A brief discussion on therapeutic options one may consider after progression on lenvatinib therapy for iodine-refractory DTC.

Practical Advice and Resources for Patients on Systemic Therapy for DTC

May 5th 2022

Shared practical advice for patients who may be undergoing treatment for iodine-refractory differentiated thyroid cancer.

Patient Experience with Systemic Therapy-Related Toxicities in Metastatic RCC

May 2nd 2022

Meryl Uranga describes her personal experience with managing the side effects of treatment for clear cell renal cell carcinoma.

Adverse Events Associated with IO-TKI Therapies in Metastatic Clear Cell RCC

May 2nd 2022

An overview of side effects commonly seen with lenvatinib plus pembrolizumab for the treatment of clear cell renal cell carcinoma.

Educated Patient® Kidney Cancer Summit Combination Therapy Panel: April 9, 2022

May 1st 2022

Watch Dr. Thomas Hutson, Dr. Saby George, Dr. Jeff Yorio and Louise Gunter answer questions about combination therapy, during the CURE Educated Patient Kidney Cancer Summit.

Educated Patient® Kidney Cancer Summit IO/TKI-Related Side Effects Presentation: April 9, 2022

April 30th 2022

Watch Louise Gunter, from Texas Oncology, discuss IO/TKI-related side effects, during the CURE Educated Patient Kidney Cancer Summit.

The Importance of Molecular Profiling and Patient Education in NSCLC

April 29th 2022

Shared insight on how molecular profiling can impact the management of EGFR exon 20 insertion–positive NSCLC and how patient advocacy groups can help patients to interpret test results.

Overview of EGFR Exon 20 and Molecular Testing in NSCLC

April 29th 2022

Experts explain the presence and role of EGFR exon 20 insertion mutations in non–small cell lung cancer and highlight the role of molecular profiling.

Educated Patient® Kidney Cancer Summit IO/TKI Therapies Presentation: April 9, 2022

April 29th 2022

Watch Dr. Jeff Yorio, from Texas Oncology, discuss treatment with the combination of immunotherapy and tyrosine kinase inhibitors, during the CURE Educated Patient Kidney Cancer Summit.

Educated Patient® Kidney Cancer Summit IO/IO Therapies Presentation: April 9, 2022

April 28th 2022

Watch Dr. Saby George, from Roswell Park Comprehensive Cancer Center, discuss treatment with the combination of immunotherapies, during the CURE Educated Patient Kidney Cancer Summit.

Communicating With Care Providers While on Therapy for DTC

April 28th 2022

Discussion on how best to communicate with care providers while undergoing therapy for iodine-refractory differentiated thyroid cancer.

Radioiodine-Refractory DTC: Dosing Considerations for Lenvatinib Therapy

April 28th 2022

Considerations for how dosing and dose reductions can be used to optimize use of lenvatinib for iodine-refractory DTC.

Educated Patient® Kidney Cancer Summit Panel on Communicating With Providers About Immunotherapy/TKI Combo Treatment: April 9, 2022

April 27th 2022

Watch Dr. Thomas Hutson, Louise Gunter and Meryl Uranga discuss communicating with a care team about treatment with immunotherapy combined with tyrosine kinase inhibitors, during the CURE Educated Patient Kidney Cancer Summit.

Educated Patient® Kidney Cancer Summit Panel on Side Effects from Immunotherapy/TKI Combo Treatment: April 9, 2022

April 26th 2022

Watch Dr. Thomas Hutson, Louise Gunter and Meryl Uranga discuss side effects and dose reductions after treatment with immunotherapy combined with tyrosine kinase inhibitors, during the CURE Educated Patient Kidney Cancer Summit.

Educated Patient® Kidney Cancer Summit Panel on Immunotherapy/TKI Combo Treatment: April 9, 2022

April 25th 2022

Watch Dr. Thomas Hutson, Louise Gunter and Meryl Uranga discuss the treatment of combining immunotherapy with tyrosine kinase inhibitors, during the CURE Educated Patient Kidney Cancer Summit.

Educated Patient® Kidney Cancer Summit Frontline Therapy Panel: April 9, 2022

April 24th 2022

Watch Dr. Thomas Hutson, Dr. Jose Karam, Dr, Naomi Haas, and Kiran Kehoe answer questions about frontline therapy during the CURE Educated Patient Kidney Cancer Summit.

Educated Patient® Kidney Cancer Summit Adjuvant Therapy Options Presentation: April 9, 2022

April 23rd 2022

Watch Dr. Naomi Haas, from Abramson Cancer Center, discuss adjuvant therapy options, during the CURE Educated Patient Kidney Cancer Summit.

Educated Patient® Kidney Cancer Summit Surgical Options Presentation: April 9, 2022

April 22nd 2022

Watch Dr. Jose Karam, from The University of Texas MD Anderson Cancer Center, discuss surgical options, during the CURE Educated Patient Kidney Cancer Summit.

Role of Nurses in the Multidisciplinary Management of RCC

April 21st 2022

Clinical nurse Kiran Virdee explains why a multidisciplinary treatment approach to clear cell renal cell carcinoma is beneficial.

Factors for Consideration in RCC Treatment Decision-Making

April 21st 2022

An oncologist describes the necessity of discussing options with a patient when picking a treatment approach for clear cell renal cell carcinoma.

Receiving Lenvatinib Therapy for Iodine-Refractory DTC

April 21st 2022

Expert and patient perspectives on receiving lenvatinib therapy for iodine-refractory differentiated thyroid cancer.

Educated Patient® Kidney Cancer Summit Diagnosis Panel: April 9, 2022

April 21st 2022

Watch Dr. Vitaly Margulis, Dr. Rana Mckay and Kwame Garrett-Price answer questions about kidney cancer diagnoses during the CURE Educated Patient Kidney Cancer Summit.

Radioiodine-Refractory DTC: An Overview of Work-up and Treatment Options

April 21st 2022

Health care specialists share insight on the work-up of patients with iodine-refractory differentiated thyroid cancer and how this may affect systemic therapy options.

How a Standardized Staging System Helps Patients, Providers Choose Best Kidney Cancer Treatment Options

April 20th 2022

By understanding what a TNM staging score is, patients and clinicians can determine the best line of treatment for their kidney cancer, as well as what the survivorship care plan should be.

Advertisement
Advertisement